HLS Therapeutics
$3.21
5
+$0+0% Friday 15:36
Statistics
Day High
3.21
Day Low
3.21
52W High
4.02
52W Low
2.96
Volume
-
Avg. Volume
-
Mkt Cap
100.39M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Dividends
0%Dividend Yield
Jun 23
$0.04
Mar 23
$0.04
Dec 22
$0.04
Sep 22
$0.04
Jun 22
$0.04
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
7MayExpected
Expected EPS
-0.12
Actual EPS
N/A
Financials
-34.71%Profit Margin
Unprofitable113.24MRevenue
-39.31MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow HLTRF. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN
Mkt Cap316.3B
Novartis
NVS
Mkt Cap297.35B
Pfizer
PFE
Mkt Cap153.13B
Merck
MRK
Mkt Cap300.2B
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Abbvie
ABBV
Mkt Cap367.8B
AMGEN
AMGN
Mkt Cap189.22B
GSK
GSK
Mkt Cap116.3B
Sanofi
SNY
Mkt Cap113.88B
Johnson & Johnson
JNJ
Mkt Cap574.66B
About
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
Show more...
CEO
Mr. Craig Stuart Millian M.B.A.
Employees
92
Country
Canada
ISIN
CA40390B1094
Listings
0 Comments
Share your thoughts
FAQ
What is HLS Therapeutics stock price today?▼
The current price of HLTRF is $3.21 USD — it has increased by +0% in the past 24 hours. Watch HLS Therapeutics stock price performance more closely on the chart.
What is HLS Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange HLS Therapeutics stocks are traded under the ticker HLTRF.
What is HLS Therapeutics market cap?▼
Today HLS Therapeutics has the market capitalization of 100.39M
When is the next HLS Therapeutics earnings date?▼
HLS Therapeutics is going to release the next earnings report on May 07, 2026.
What were HLS Therapeutics earnings last quarter?▼
HLTRF earnings for the last quarter are -0.04 USD per share, whereas the estimation was -0.03 USD resulting in a -33.33% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is HLS Therapeutics revenue for the last year?▼
HLS Therapeutics revenue for the last year amounts to 113.24M USD.
What is HLS Therapeutics net income for the last year?▼
HLTRF net income for the last year is -39.31M USD.
Does HLS Therapeutics pay dividends?▼
Yes, HLTRF dividends are paid quarterly. The last dividend per share was 0.04 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does HLS Therapeutics have?▼
As of April 17, 2026, the company has 92 employees.
In which sector is HLS Therapeutics located?▼
HLS Therapeutics operates in the Health & Wellness sector.
When did HLS Therapeutics complete a stock split?▼
HLS Therapeutics has not had any recent stock splits.
Where is HLS Therapeutics headquartered?▼
HLS Therapeutics is headquartered in Etobicoke, Canada.